SEC.gov | Daniel V.T. Catenacci sec.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sec.gov Daily Mail and Mail on Sunday newspapers.
January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary. | January 5, 2023
Amgen’s drug portfolio boasts several biologic drugs that are blockbuster sellers. In acquiring ChemoCentryx for $3.7 billion, the pharmaceutical giant gains a company entirely focused on developing small molecule alternatives to biologic medicines.